LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

The non-Hodgkin’s lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in targeted and precision therapies, the launch of ...

Second-quarter earnings come amid many high-level challenges for the biopharma industry. How will these five closely watched ...

Roche/AbbVie’s cancer drug venetoclax, which is set to become standard of care in chronic lympocytic leukaemia, could further improve prognosis earlier in the disease according to a UK expert ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...